Zeta Research Srl © 2020. All rights reserved
P.IVA IT01028800322
PREFER
development of a biocompatible PRoduct for the tErapy of FER (wounds) difficult wounds
Difficult wounds include all skin lesions characterized by the absence or low speed of healing, resulting from chronic diseases, infections, diabetes, immune diseases, trauma, amputations, post-operative complications, etc.
These are serious conditions that can lead to amputation and are very common especially in the elderly population (prevalence 3% of the population over 65 years old).
In Italy alone, it is estimated that 2 million individuals are affected by these conditions.
PREFER is a study that aims to develop an advanced therapy medicinal product capable of revascularizing tissues affected by difficult wounds, and in doing so, healing them.
IN VITRO PRE-CLINICAL STUDY
IN VIVO PRE-CLINICAL STUDY
ATMP
In-vivo efficacy tests to evaluate healing from a clinical, histological, and functional point of view.
Development of an advanced therapy medicinal product (ATMP) to be developed at reduced costs through the use of automated bioreactors.
Identification, evaluation and use of extracellular matrices to support the growth of human endothelial cells.
30
€ 1,102.085
€ 718,486.92
MONTHS
TOTAL PROJECT
TOTAL CONTRIBUTION
This project is funded by:
Operational Programme of the European Regional Development Fund 2014-2020 of Friuli Venezia Giulia.
Do you want to know more or receive material about PREFER?
Fill out our online form to send an email to our team.
Zeta Research Srl © 2020. All rights reserved
P.IVA IT01028800322